---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009128"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:30:48.375346+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lipocine reports FY2023 net loss $16.4M; signs TLANDO license deal with Verity Pharma for $11M upfront

## Summary
- Net loss $16.4M ($3.14 diluted EPS) in 2023 vs $10.8M loss in 2022; revenue reversal of $2.9M from Antares termination.
- Entered exclusive license with Verity Pharma for TLANDO in U.S./Canada; received $7.5M of $11M upfront, up to $259M milestones, 12-18% royalties.
- Cash $22.0M at 2023 year-end; subsequent $7.5M from Verity brings pro-forma cash to ~$29.5M.
- LPCN 1154 oral brexanolone: positive PK bridge study; pivotal study starts Q1'24, NDA filing expected Q4'24.
- LPCN 1148 Phase 2 POC met primary endpoint for decompensated cirrhosis; fewer HE events, symptom improvement.

## SEC filing metadata
- accession: 0001493152-24-009128
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315224009128/0001493152-24-009128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315224009128/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009128
- JSON: https://secwatch.observer/filing/0001493152-24-009128.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009128.txt

## Key facts
- Earnings Releases
  Lipocine Inc. reported the year ended December 31, 2023 results: revenue $2.9 million, net income net loss of $16.4 million, EPS ($3.14) per diluted share.
  - Period: the year ended December 31, 2023
  - Revenue: $2.9 million
  - Net income: net loss of $16.4 million
  - EPS: ($3.14) per diluted share
  - Result: reported results
  source text: per diluted share, for the year ended December 31, 2022. During 2023 Lipocine recognized a non-cash minimum guaranteed royalties reversal of variable consideration revenue of $2.9 million related to the termination of the Antares License Agreement. The reversal of revenue is due to the fact that, as a result of the termination of the license agreement, the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1535955/000149315224009128/0001493152-24-009128-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.